Christos Patriotis

Christos Patriotis

Auto-generated profile, based on publicly available information

Christos Patriotis

Division of Cancer Prevention, National Cancer Institute , Bethesda, MD

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
GKGabriel A. Kwong
Gabriel A. Kwong
SGSharmistha Ghosh
Sharmistha Ghosh
LGLena Gamboa
Lena Gamboa
CPChristos Patriotis
Christos Patriotis
SSSudhir Srivastava
Sudhir Srivastava
SBSangeeta N. Bhatia
Sangeeta N. Bhatia

22 March 2024 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
WRWendy S. Rubinstein
Wendy S. Rubinstein
CPChristos Patriotis
Christos Patriotis
ADAnthony Dickherber
Anthony Dickherber
PHPaul K. J. Han
Paul K. J. Han
HKHormuzd A. Katki
Hormuzd A. Katki
LMLori M. Minasian
Lori M. Minasian
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective screening methods. However, these tests have unknown and unquantified benefits and harms. MCD tests differ from conventional cancer screening tests in that the organ responsible for a positive test is unknown, and a broad diagnostic workup may be necessary to confirm the location and type of underlying cancer. Among two prospective studies involving greater than 16,000 individuals, MCD tests identified those who had some cancers without currently recommended screening tests, including pancreas, ovary, liver, uterus, small intestine, oropharyngeal, bone, thyroid, and hematologic malignancies, at early stages. Reported MCD test sensitivities range from 27% to 95% but differ by organ and are lower for early stage cancers, for which treatment toxicity would be lowest and the potential for cure might be highest. False reassurance from a negative MCD result may reduce screening adherence, risking a loss in proven public health benefits from standard‐of‐care screening. Prospective clinical trials are needed to address uncertainties about MCD accuracy to detect different cancers in asymptomatic individuals, whether these tests can detect cancer sufficiently early for effective treatment and mortality reduction, the degree to which these tests may contribute to cancer overdiagnosis and overtreatment, whether MCD tests work equally well across all populations, and the appropriate diagnostic evaluation and follow‐up for patients with a positive test.

2 December 2022 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
LMLori M Minasian
Lori M Minasian
PPPaul Pinsky
Paul Pinsky
HKHormuzd A Katki
Hormuzd A Katki
TDTony Dickherber
Tony Dickherber
PHPaul K J Han
Paul K J Han
PCPhilip E Castle
Philip E Castle
Blood-based assays using various technologies and biomarkers are in commercial development for the purpose of detecting multiple cancer types concurrently at an early stage of disease. These multicancer early detection (MCED) assays have the potential to improve the detection of cancers, particularly those for which no current screening modality exists. However, the unknown clinical benefits and harms of using MCED assays for cancer screening necessitate the development and implementation of a randomized controlled trial (RCT) to ascertain their clinical effectiveness. This was the consensus of experts at a National Cancer Institute–hosted workshop to discuss initial design concepts for such a trial. Using these assays to screen simultaneously for multiple cancers poses novel uncertainties for patient care compared with conventional screening tests for single cancers, such as establishing the diagnostic workup to confirm the presence of cancer at any organ site; clarifying appropriate follow-up for a positive assay for which there is no definitive diagnosis; identifying potential harms such as overdiagnosis of indolent disease; determining clinically effective and efficient strategies for disseminating MCED screening in real-world practice; and understanding the ethical implications, such as potentially alleviating or exacerbating existing health disparities. These assays present new and complex challenges for designing an RCT. Issues that emerged from the meeting centered around the need for a flexibly designed, clinical utility RCT to rigorously capture the evidence required to fully understand the net benefit of this promising technology. Specific topic areas were endpoints, screening protocols, recruitment, diagnostic pathway, pilot phase, data elements, specimen collection, and ethical considerations.

6 November 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
RERuth Etzioni
Ruth Etzioni
RGRoman Gulati
Roman Gulati
CPChristos Patriotis
Christos Patriotis
CRCarolyn Rutter
Carolyn Rutter
YZYingye Zheng
Yingye Zheng
ZFZiding Feng
Ziding Feng
Novel liquid biopsy technologies are creating a watershed moment in cancer early detection. Evidence supporting population screening is nascent, but a rush to market the new tests is prompting cancer early detection researchers to revisit the standard blueprint that the Early Detection Research Network established to evaluate novel screening biomarkers. In this commentary, we review the Early Detection Research Network’s Phases of Biomarker Development (PBD) for rigorous evaluation of novel early detection biomarkers and discuss both hazards and opportunities involved in expedited evaluation. According to the PBD, for a biomarker-based test to be considered for population screening, 1) test sensitivity in a prospective screening setting must be adequate, 2) the shift to early curable stages must be meaningful, and 3) any stage shift must translate into clinically significant mortality benefit. In the past, determining mortality benefit has required lengthy randomized screening trials, but interest is growing in expedited trial designs with shorter-term endpoints. Whether and how best to use such endpoints in a manner that retains the rigor of the PBD remains to be determined. We discuss how computational disease modeling can be harnessed to learn about screening impact and meet the needs of the moment.

22 March 2004 in Bioinformatics
Verified
Journal Article
Open access
PDF file
Radka StoyanovaRadka Stoyanova
Radka Stoyanova
TQTroy D. Querec
Troy D. Querec
TBTruman R. Brown
Truman R. Brown
CPChristos Patriotis
Christos Patriotis
Motivation: Detailed comparison and analysis of the output of DNA gene expression arrays from multiple samples require global normalization of the measured individual gene intensities from the different hybridizations. This is needed for accounting for variations in array preparation and sample hybridization conditions. Results: Here, we present a simple, robust and accurate procedure for the global normalization of datasets generated with single-channel DNA arrays based on principal component analysis. The procedure makes minimal assumptions about the data and performs well in cases where other standard procedures produced biased estimates. It is also insensitive to data transformation, filtering (thresholding) and pre-screening.

4 August 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
ELElyse LeeVan
Elyse LeeVan
ASAmanda L. Skarlupka
Amanda L. Skarlupka
CPChristos Patriotis
Christos Patriotis
WRWendy S. Rubinstein
Wendy S. Rubinstein
PPPaul F. Pinsky
Paul F. Pinsky
LMLori M. Minasian
Lori M. Minasian
Background: The Cancer Screening Research Network is a new clinical trials network funded by the NCI. The first Cancer Screening Research Network study, the Vanguard Study (VS), will assess the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials. Methods: This article describes the framework NCI developed to engage MCD assay developers, evaluate emerging technologies using biobank reference sets, and select fit-for-purpose MCD assays for inclusion in the VS. Results: NCI evaluated 23 technologically diverse MCD assays, all utilizing machine learning and artificial intelligence components. Nine assays underwent blinded performance evaluations using specimens from three biobanks. Assay developers were provided with independent assessments of their assays, which enabled them to make further assay refinements to enhance performance. The assay selection process resulted in participation by two assay companies in the VS. Conclusions: NCI created a fair and transparent process to streamline the evaluation of assay performance and to select promising assays for clinical research and public health initiatives. Impact: Significant resources are required for large-scale cancer screening trials; therefore, promising technologies must be prioritized for inclusion in a definitive trial. NCI’s assay selection framework can be used and repurposed by other networks and institutions.